NCT07036991 A Cohort Study Comparing PCSK9 Inhibitor Plus Statin With Statin Monotherapy for Carotid Artery Stenosis
| NCT ID | NCT07036991 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Changhai Hospital |
| Condition | Carotid Artery Stenosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 406 participants |
| Start Date | 2025-09-05 |
| Primary Completion | 2027-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 406 participants in total. It began in 2025-09-05 with a primary completion date of 2027-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A multicenter cohort study
Eligibility Criteria
Inclusion Criteria: Clinical inclusion criteria: 1. Age ≥ 18 years. 2. Asymptomatic mild-to-moderate carotid artery stenosis confirmed by CTA, MRA, ultrasound, or DSA, with no anticipated need for surgical intervention. 3. Modified Rankin Scale (mRS) score ≤ 2 4. Signed informed consent form obtained from the subject Ultrasound Inclusion Criteria: Carotid ultrasound showing a plaque burden rate ≥30% at the most stenotic cross-sectional site of the carotid artery (common carotid artery or proximal C1 segment of the internal carotid artery). Exclusion Criteria: 1. Non-atherosclerotic carotid stenosis, including arterial dissection, Takayasu arteritis, radiation-induced vasculopathy, fibromuscular dysplasia, neurofibromatosis, suspected vasospasm, or recanalized vascular embolism. 2. Known cardioembolic sources: mitral stenosis, mechanical heart valve, infective endocarditis, intracardiac thrombus/vegetation, myocardial infarction within 3 months, dilated cardiomyopathy, chronic/paroxysmal atrial fibrillation. (Confound ASCVD outcome assessment.) 3. History of cerebrovascular, coronary, or peripheral arterial endovascular intervention within 30 days before enrollment or anticipated surgery within the next 6 months. 4. History of ischemic stroke, transient ischemic attack (TIA), or intracranial hemorrhage (parenchymal, subarachnoid, subdural, or epidural) before enrollment. 5. Pre-existing intracranial tumor, cerebral aneurysm, or arteriovenous malformation. 6. History of thromboembolic diseases (pulmonary embolism, mesenteric embolism, lower limb arterial embolism) or coronary atherosclerotic heart disease. 7. Severe neurological deficits impairing independent living; diagnosed dementia/psychiatric disorders interfering with follow-up; or life expectancy \<3 years due to other conditions. 8. Severe/unstable comorbidities: Severe heart failure (NYHA Class III/IV or LVEF \<30%), Renal failure (serum creatinine \>264 μmol/L or creatinine clearance \<0.6 mL/s), Severe hepatic dysfunction (ALT/AST \>3× upper limit of normal), CK \>5× upper limit of normal, Active malignancy. 9. Use of PCSK9 inhibitors or CETP inhibitors within 24 weeks before enrollment. 10. The subjects have taken strong inhibitor drugs of cytochrome P-450 3A4 (including: adagrasib, atazanavir, ceritinib, clarithromycin, darunavir, idelalisib, indinavir, itraconazole, ketoconazole, levonorgestrel, lonafarnib, lopinavir, mifepristone, nefazodone, nelfinavir, nirmatrelvir/ritonavir, Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets), mbitasvir/paritaprevir/ritonavir and dasabuvir, posaconazole, co-formulations containing ritonavir and ritonavir itself, saquinavir, erythromycin, tucatinib, voriconazole) within one month before randomization, or may require such drugs during the study period. 11. Pregnancy or lactation. 12. Concurrent participation in another trial that may affect outcome assessment. 13. Other situations that the investigator believes may cause significant harm to the subjects if they participate in this trial. 14. Situations where the investigator believes there are other vascular lesions that may lead to short - term ischemic events and surgeries.
Contact & Investigator
Jianmin Liu
PRINCIPAL INVESTIGATOR
Changhai Hospital
Frequently Asked Questions
Who can join the NCT07036991 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Carotid Artery Stenosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07036991 currently recruiting?
Yes, NCT07036991 is actively recruiting participants. Contact the research team at lqeimm@126.com for enrollment information.
Where is the NCT07036991 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07036991 clinical trial?
NCT07036991 is sponsored by Changhai Hospital. The principal investigator is Jianmin Liu at Changhai Hospital. The trial plans to enroll 406 participants.